

SUPPLEMENTARY MATERIAL

Table S1 Studies included in the 35-study pool

Reference	Study design and duration included	N	Treatment	ClinicalTrials.gov identifier
Exenatide BID				
Fineman et al, 2003 [1]	R, DB, PC 4 weeks	109	Exenatide 0.08 µg/kg BID or TID Placebo	—
DeFronzo et al, 2005 [2]	R, DB, PC 30 weeks	336	Exenatide BID 5 µg for 4 weeks then 5 or 10 µg Placebo	NCT00039013
Buse et al, 2004 [3]	R, DB, PC 30 weeks	377	Exenatide BID 5 µg for 4 weeks then 10 µg Placebo	NCT00039026
Bunck et al, 2009 [4]	R, OL, AC 52 weeks	69	Exenatide BID 5 µg for 4 weeks then 10 µg (titrated to maximum of 20 µg TID) Insulin glargine	NCT00097500
Kendall et al, 2005 [5]	R, DB, PC 30 weeks	733	Exenatide BID 5 µg for 4 weeks then 5 or 10 µg Placebo	NCT00035984
Poon et al, 2005 [6]	R, DB, PC 4 weeks	156	Exenatide BID 2.5, 5, 7.5, or 10 µg Placebo	NCT00044694

Reference	Study design and duration included	N	Treatment	ClinicalTrials.gov identifier
Nelson et al, 2007 [7]	R, DB, PC 4 weeks	99	Exenatide BID 10 µg, exenatide QD 10 µg, or exenatide QD 20 µg Placebo	NCT00085969
Davies et al, 2009 [8]	R, OL, AC 26 weeks	235	Exenatide BID 5 µg for 4 weeks then 10 µg Insulin glargine	NCT00360334
H8O-CA-GWCE ClinicalTrials.gov (NCT00701935)	R, DB, PC 26 weeks	80	Exenatide BID 5 µg for 4 weeks then 10 µg Placebo	NCT00701935
Gallwitz et al, 2012 [9]	R, OL, AC 234 weeks (unpublished data)	1017	Exenatide BID 5 µg for 4 weeks then 10 µg Glimepiride	NCT00359762
Diamant et al, 2014 [10]	R, OL, AC 30 weeks	627	Exenatide BID 5 µg for 4 weeks then 10 µg Insulin lispro	NCT00960661
Kadowaki et al, 2009 [11]	R, partial DB, PC 12 weeks	151	Exenatide BID 2.5, 5, or 10 µg Placebo	NCT00382239
Kadowaki et al, 2011 [12]	R, DB, PC 24 weeks	179	Exenatide BID 5 µg for 4 weeks then 5 or 10 µg Placebo	NCT00577824

Reference	Study design and duration included	N	Treatment	ClinicalTrials.gov identifier
Heine et al, 2005 [13]	R, OL, AC 26 weeks	549	Exenatide BID 5 µg for 4 weeks then 10 µg Insulin glargine	NCT00082381
Nauck et al, 2007 [14]	R, OL, AC 52 weeks	501	Exenatide BID 5 µg for 4 weeks then 10 µg Insulin aspart 30/70	NCT00082407
Davis et al, 2007 [15]	R, OL, AC 16 weeks	49	Exenatide BID 5 µg for 4 weeks then 10 µg Insulin	NCT00099333
Barnett et al, 2007 [16]	R, OL, AC 16 weeks	138	Exenatide BID 5 µg for 4 weeks then 10 µg Insulin glargine	NCT00099619
Zinman et al, 2007 [17]	R, DB, PC 16 weeks	233	Exenatide BID 5 µg for 4 weeks then 10 µg Placebo	NCT00099320
Gao et al, 2009 [18]	R, DB, PC 16 weeks	467	Exenatide BID 5 µg for 4 weeks then 10 µg Placebo	NCT00324363
Moretto et al, 2008 [19]	R, DB, PC 24 weeks	232	Exenatide BID 5 µg for 4 weeks then 5 or 10 µg Placebo	NCT00381342

Reference	Study design and duration included	N	Treatment	ClinicalTrials.gov identifier
Gill et al, 2010 [20]	R, DB, PC 12 weeks	54	Exenatide BID 5 µg for 4 weeks then 10 µg Placebo	NCT00516074
Liutkus et al, 2010 [21]	R, DB, PC 26 weeks	165	Exenatide BID 5 µg for 4 weeks then 10 µg Placebo	NCT00603239
Gallwitz et al, 2011 and 2010 [22, 23]	R, OL, AC 26 weeks	480	Exenatide BID 5 µg for 4 weeks then 10 µg Insulin aspart 30/70	NCT00434954
DeFronzo et al, 2010 [24]	R, OL, AC 20 weeks	137	Exenatide BID 5 µg for 4 weeks then 10 µg Rosiglitazone Exenatide BID 10 µg plus rosiglitazone	NCT00135330
Apovian et al, 2010 [25]	R, DB, PC 24 weeks	194	Exenatide BID 5 µg for 4 weeks then 10 µg Placebo	NCT00375492
Buse et al, 2011 [26]	R, DB, PC 30 weeks	259	Exenatide BID 5 µg for 4 weeks then 10 µg Placebo	NCT00765817
Exenatide QW Kim et al, 2007 [27]	R, DB, PC 15 weeks	44	Exenatide QW 0.8 or 2 mg Placebo	NCT00103935

Reference	Study design and duration included	N	Treatment	ClinicalTrials.gov identifier
Bergental et al, 2010 [28]	R, DB, AC 26 weeks	491 total (325 in analysis)	Exenatide QW 2 mg Pioglitazone Sitagliptin (not included in analysis)	NCT00637273
Davies et al, 2013 [29]	R, OL, AC 26 weeks	216	Exenatide QW 2 mg Insulin detemir	NCT01003184
Iwamoto et al, 2009 [30]	R, DB, PC 10 weeks	30	Exenatide QW 0.8 or 2 mg Placebo	NCT00612794
Inagaki et al, 2012 [31]	R, OL, AC 26 weeks	427	Exenatide QW 2 mg Insulin glargine	NCT00935532
Diamant et al, 2012 and 2014 [32, 33]	R, OL, AC 3 years	456	Exenatide QW 2 mg Insulin glargine	NCT00641056
Russell-Jones et al, 2012 [34]	R, DB, AC 26 weeks	820 total (657 in analysis)	Exenatide QW 2 mg Metformin Pioglitazone Sitagliptin (not included in analysis)	NCT00676338
Exenatide QW Suspension				
MacConell et al, 2012 [35]	Two-cohort single and repeat dose; only cohort 2 (patients with diabetes receiving repeat doses) included in analysis 12 weeks	65 total (35 in analysis)	Exenatide QW suspension 2 mg Placebo	NCT00894322

Reference	Study design and duration included	N	Treatment	ClinicalTrials.gov identifier
Gadde et al, 2017 [36]	R, OL, 3-arm 28 weeks	365 total (242 in analysis)	Exenatide QW suspension 2 mg Placebo Sitagliptin (not included in analysis)	NCT01652729

AC active-controlled, *BID* twice daily, *DB* double-blind, *OL* open-label, *PC* placebo-controlled, *QD* once daily, *QW* once weekly, *R* randomized, *TID* three times daily

REFERENCES

1. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. *Diabetes Care*. 2003;26:2370–7.
2. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care*. 2005;28:1092–100.
3. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care*. 2004;27:2628–35.
4. Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. *Diabetes Care*. 2009;32:762–8.
5. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care*. 2005;28:1083–91.
6. Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. *Diabetes Technol Ther*. 2005;7:467–77.
7. Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. *Diabetes Technol Ther*. 2007;9:317–26.
8. Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes Obes Metab*. 2009;11:1153–62.
9. Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. *Lancet*. 2012;379:2270–8.
10. Diamant M, Nauck MA, Shaginian R, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. *Diabetes Care*. 2014;37:2763–73.
11. Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. *Endocr J*. 2009;56:415–24.
12. Kadowaki T, Namba M, Imaoka T, et al. Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. *J Diabetes Investig*. 2011;2:210–7.
13. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med*. 2005;143:559–69.
14. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic

- insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. *Diabetologia*. 2007;50:259–67.
15. Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. *Diabetes Care*. 2007;30:2767–72.
 16. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. *Clin Ther*. 2007;29:2333–48.
 17. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med*. 2007;146:477–85.
 18. Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. *Diabetes Res Clin Pract*. 2009;83:69–76.
 19. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther*. 2008;30:1448–60.
 20. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. *Cardiovasc Diabetol*. 2010;9:6.
 21. Liutkus J, Rosas Guzman J, Norwood P, et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. *Diabetes Obes Metab*. 2010;12:1058–65.
 22. Gallwitz B, Bohmer M, Segiet T, et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. *Diabetes Care*. 2011;34:604–6.
 23. Gallwitz B, Böhmer M, Segiet T, et al. Exenatide vs. insulin aspart in patients with type 2 diabetes: results of a randomised, open-label study [abstract 862]. *Diabetologia*. 2010;53(Suppl 1):S343.
 24. DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on β -cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. *Diabetes Care*. 2010;33:951–7.
 25. Apovian CM, Bergenstal RM, Cuddihy RM, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. *Am J Med*. 2010;123:468, e9–17.
 26. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. *Ann Intern Med*. 2011;154:103–12.
 27. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. *Diabetes Care*. 2007;30:1487–93.
 28. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. *Lancet*. 2010;376:431–9.

29. Davies M, Heller S, Sreenan S, et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. *Diabetes Care*. 2013;36:1368–76.
30. Iwamoto K, Nasu R, Yamamura A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. *Endocr J*. 2009;56:951–62.
31. Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. *Clin Ther*. 2012;34:1892–908.
32. Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. *Diabetes Care*. 2012;35:683–9.
33. Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. *Lancet Diabetes Endocrinol*. 2014;2:464–73.
34. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. *Diabetes Care*. 2012;35:252–8.
35. MacConell L, Flore S, Cirincione B, et al. Pharmacokinetics and pharmacodynamics of a new exenatide formulation, exenatide suspension [abstract 1099-P]. *Diabetes*. 2012;61(Suppl 1):A283–4.
36. Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P, DURATION-NEO-2 study investigators. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study. *Diabetes Obes Metab*. 2017;19:979–88.